20世纪90年代中期,人们发现西罗莫司对T淋巴细胞增殖有抑制作用,故将其用于抗肿瘤细胞的治疗。目前上市的西罗莫司剂型有胶囊剂、口服液、片剂,但由于西罗莫司脂溶性好,而水溶性较差,故其生物利用度不高,且容易发生不良反应。本文通过检索近几年Pubmed、Springer、CJFD、维普中文期刊数据库、万方数据库中收录的相关文献,综述西罗莫司新剂型的研究情况。以期为西罗莫司的深入研究提供参考依据。 In the mid 90s of the 20th century, sirolimus was found to inhibit the proliferation of T lymphocytes, so it was used in the treatment of anti-tumor cells. At present, sirolimus is available in the form of capsules, oral liquids and tablets. However, due to the good solubility of sirolimus and poor water solubility, the bioavailability of sirolimus is not high, and adverse reactions are prone to occur. In this paper, we review the recent literature on Pubmed, Springer, CJFD, VIP Chinese Periodical Databases and Wanfang Database, and review the research on new formulations of sirolimus. In order to provide a reference for the further study of sirolimus.